Geron Corporation (GERN) stock has gained 17.44% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With GERN Stock Today?
Geron Corporation (GERN) stock is trading at $2.02 as of 12:13 PM on Tuesday, Feb 2, a gain of $0.12, or 6.32% from the previous closing price of $1.90. The stock has traded between $1.91 and $2.02 so far today. Volume today is low. So far 2,159,776 shares have traded compared to average volume of 2,957,326 shares.
To screen for more stocks like Geron Corporation click here.
More About Geron Corporation
Geron Corp is a clinical stage biopharmaceutical company focused on research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses the global rights to this drug.
Click Here to get the full Stock Score Report on Geron Corporation (GERN) Stock.
